CN107206078A - 特异性结合脑源性神经营养因子前体蛋白的结合分子的应用 - Google Patents

特异性结合脑源性神经营养因子前体蛋白的结合分子的应用 Download PDF

Info

Publication number
CN107206078A
CN107206078A CN201580075642.0A CN201580075642A CN107206078A CN 107206078 A CN107206078 A CN 107206078A CN 201580075642 A CN201580075642 A CN 201580075642A CN 107206078 A CN107206078 A CN 107206078A
Authority
CN
China
Prior art keywords
seq
probdnf
antibody
mouse
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580075642.0A
Other languages
English (en)
Inventor
李昌琪
王华茂
戴茹萍
蔡秀梅
周新富
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Yile Biotechnology Ltd
Original Assignee
Shanghai Yile Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Yile Biotechnology Ltd filed Critical Shanghai Yile Biotechnology Ltd
Publication of CN107206078A publication Critical patent/CN107206078A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明公开了特异性结合脑源性神经营养因子前体蛋白(proBDNF)的结合分子的应用。所述proBDNF的结合分子，特别是proBDNF的单克隆抗体，能够用于预防、缓解或治疗自身免疫性疾病。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201580075642.0A 2014-12-19 2015-12-18 特异性结合脑源性神经营养因子前体蛋白的结合分子的应用 Pending CN107206078A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410811678.8A CN105770889B (zh) 2014-12-19 2014-12-19 特异性结合脑源性神经营养因子前体蛋白的结合分子的应用
CN2014108116788 2014-12-19
PCT/CN2015/097820 WO2016095839A1 (zh) 2014-12-19 2015-12-18 特异性结合脑源性神经营养因子前体蛋白的结合分子的应用

Publications (1)

Publication Number Publication Date
CN107206078A true CN107206078A (zh) 2017-09-26

Family

ID=56125955

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201410811678.8A Active CN105770889B (zh) 2014-12-19 2014-12-19 特异性结合脑源性神经营养因子前体蛋白的结合分子的应用
CN201580075642.0A Pending CN107206078A (zh) 2014-12-19 2015-12-18 特异性结合脑源性神经营养因子前体蛋白的结合分子的应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201410811678.8A Active CN105770889B (zh) 2014-12-19 2014-12-19 特异性结合脑源性神经营养因子前体蛋白的结合分子的应用

Country Status (12)

Country Link
US (2) US10556947B2 (zh)
EP (1) EP3235507B1 (zh)
JP (2) JP6758317B2 (zh)
KR (1) KR20170104487A (zh)
CN (2) CN105770889B (zh)
AU (1) AU2015366363B2 (zh)
CA (1) CA2971823A1 (zh)
ES (1) ES2826523T3 (zh)
HK (1) HK1244712A1 (zh)
MX (1) MX2017007970A (zh)
SG (1) SG11201705004VA (zh)
WO (1) WO2016095839A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112165957A (zh) * 2018-03-26 2021-01-01 上海易乐生物技术有限公司 proBDNF调节剂在B细胞相关疾病中的用途

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105770889B (zh) 2014-12-19 2021-06-01 上海易乐生物技术有限公司 特异性结合脑源性神经营养因子前体蛋白的结合分子的应用
JP2020531041A (ja) * 2017-08-28 2020-11-05 上海易楽生物技術有限公司 ポリペプチドとポリペプチドに結合される抗体
CN112574305B (zh) * 2020-12-30 2022-04-22 深圳清华大学研究院 针对前体脑源性神经营养因子的抗体及其应用
CN112961865B (zh) * 2021-02-22 2023-06-02 广西大学 一种利用基因编辑鸡生物反应器表达的重组曲妥珠单抗及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010093904A2 (en) * 2009-02-12 2010-08-19 Curna, Inc. Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
CN104774264A (zh) * 2014-01-15 2015-07-15 上海易乐生物技术有限公司 抗人proBDNF单克隆抗体及其在疼痛中的作用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2481754B1 (en) 2009-09-22 2014-06-18 Shanghai Yijie Biotechnology Co., Ltd Specific binding proteins and uses thereof
CN105770889B (zh) 2014-12-19 2021-06-01 上海易乐生物技术有限公司 特异性结合脑源性神经营养因子前体蛋白的结合分子的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010093904A2 (en) * 2009-02-12 2010-08-19 Curna, Inc. Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
CN104774264A (zh) * 2014-01-15 2015-07-15 上海易乐生物技术有限公司 抗人proBDNF单克隆抗体及其在疼痛中的作用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
罗雁威 等: "脑源性神经营养因子前体蛋白生物学效应研究进展", 《现代生物医学进展》 *
许春向 等: "《现代卫生化学》", 29 February 2000, 人民卫生出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112165957A (zh) * 2018-03-26 2021-01-01 上海易乐生物技术有限公司 proBDNF调节剂在B细胞相关疾病中的用途

Also Published As

Publication number Publication date
AU2015366363A1 (en) 2017-07-13
HK1244712A1 (zh) 2018-08-17
US20170362313A1 (en) 2017-12-21
SG11201705004VA (en) 2017-07-28
KR20170104487A (ko) 2017-09-15
EP3235507B1 (en) 2020-09-30
JP2020200340A (ja) 2020-12-17
EP3235507A4 (en) 2018-06-20
EP3235507A1 (en) 2017-10-25
CA2971823A1 (en) 2016-06-23
US10556947B2 (en) 2020-02-11
AU2015366363B2 (en) 2021-09-02
US20210017264A1 (en) 2021-01-21
CN105770889A (zh) 2016-07-20
JP2018502905A (ja) 2018-02-01
MX2017007970A (es) 2018-04-13
JP6758317B2 (ja) 2020-09-23
ES2826523T3 (es) 2021-05-18
WO2016095839A1 (zh) 2016-06-23
CN105770889B (zh) 2021-06-01

Similar Documents

Publication Publication Date Title
TWI757304B (zh) Lag-3抗體、其抗原結合片段及其醫藥用途
CN110431151B (zh) 仅有重链的抗bcma抗体
TWI608015B (zh) 具有組織標的功能的抗發炎分子
CN107206078A (zh) 特异性结合脑源性神经营养因子前体蛋白的结合分子的应用
CN108026174A (zh) 人cd3结合抗体
CN106255702A (zh) 基于抗体的对转甲状腺素蛋白(ttr)淀粉样变性的疗法及其人源抗体
JP6463377B2 (ja) 抗ヒトｐｒｏＢＤＮＦモノクローナル抗体およびその疼痛における作用
RU2596403C2 (ru) Антитело к аннексину а1
KR20130060264A (ko) 위장관의 기능적 질환 또는 이상을 치료하는 제약학적 복합 조성물 및 방법들
CN109929035A (zh) 抗人ngf抗体及其制备方法和用途
BR112020003628A2 (pt) anticorpo anti-pacap
CN110494449A (zh) Alt-803与抗cd38抗体组合用于癌症治疗
JP2852705B2 (ja) 自己免疫疾患の治療
US20230159632A1 (en) Anti-il-17a antibody and use thereof
WO2021209066A1 (zh) 特异性抗原结合分子，其制备方法及医药用途
WO2020024931A1 (en) Anti-il-17a antibodies and use thereof
WO2011153592A1 (en) Therapeutic molecules

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20170926

RJ01 Rejection of invention patent application after publication